You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,354,430

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,354,430 protect, and when does it expire?

Patent 8,354,430 protects WAKIX and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 8,354,430
Title:Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Abstract: A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): ##STR00001## optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2.theta.) at,, and is administered to a patient in need thereof.
Inventor(s): Raga; Manuel (Barcelona, ES), Sallares; Juan (Barcelona, ES), Guerrero; Marta (Barcelona, ES), Guglietta; Antonio (Molins De Rei, ES), Arrang; Jean-Michel (Dourdan, ES), Schwartz; Jean-Charles (Paris, FR), Stark; Holger (Homburg, DE), Schunack; Walter (Berlin, DE), Ligneau; Xavier (Saint Gregoire, FR), Lecomte; Jeanne-Marie (Paris, FR), Ganellin; Charon (Thame, GB)
Assignee: Bioprojet (Paris, FR)
Application Number:13/491,229
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 8,354,430

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-001 Aug 14, 2019 RX Yes No   Start Trial   Start Trial METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY   Start Trial
Harmony WAKIX pitolisant hydrochloride TABLET;ORAL 211150-002 Aug 14, 2019 RX Yes Yes   Start Trial   Start Trial METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,354,430

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05100942Feb 10, 2005

International Family Members for US Patent 8,354,430

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 054734   Start Trial
Austria 391716   Start Trial
Austria 402154   Start Trial
Canada 2597016   Start Trial
China 101155793   Start Trial
Cyprus 1108428   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.